Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients
American Journal of Clinical Pathology · 13.03.2023 · 159 (3) · 255-262
DOI: 10.1093/ajcp/aqac150 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 10.01.2023. Verfasst von Yevgen Chornenkyy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, McGaw Medical Center of Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Liver Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Northwestern University.
Abstract (Originalsprache)
Background
Improvement of liver transplantation (LT) outcomes requires better understanding of factors affecting survival. The presence of RBC alloantibodies (RBCAs) on survival in LT recipients was evaluated.
Methods
This study was a single-center, retrospective cohort study reviewing transfusion records and all-cause mortality between 2002 and 2021.
Results
Between 2002 and 2021, 2079 LTs were completed, 1,396 of which met inclusion criteria (1,305 RBCA negative; 91 RBCA positive [6.5%]). The cohorts were similar in age (mean [range], 55.8 [17-79] years vs 56.8 [25-73] years; P = .41, respectively) or sex (RBCA negative, 859 [65%] men and 446 [35%] women vs RBCA positive, 51 [56%] men and 40 [44%] women; P = .0684). Of 132 RBCAs detected, 10 were most common were to E (27.27%), Jka (15.91%), K (9.09%), C (8.33%), M (6.06%), D (5.3%), Fya (4.55%), e (2.27%), c (2.27%), and Jkb (2.27%). Twenty-seven patients (29.7%) had more than 1 RBCA; the most common combinations were C with Jka (7.4%) and E with Dia (7.4%). All-cause mortality was increased in men (men, 14.45 years vs women, 17.27 years; P = .0266) and patients 65 years of age and older (≥65 years of age, 10.21 years vs <64 years of age, 17.22 years; P < .0001). The presence of RBCA (≥1) did not affect all-cause mortality (RBCA negative, 14.17 years vs RBCA positive, 15.29 years; P = .4367). The top 5 causes of death were infection (11.9%), primary malignancy (solid) (10.8%), recurrent malignancy (10.5%), cardiovascular arrest (7.1%), and pulmonary insufficiency/respiratory failure (5.7%).
Conclusions
Survival in RBCA-positive LT recipients is no different from that in RBCA-negative LT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, McGaw Medical Center of Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Surgery, McGaw Medical Center of Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
- Comprehensive Transplant Center, McGaw Medical Center of Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
ORCID-Profile: Yevgen Chornenkyy
Förderung
- Northwestern University
Zitieren
APA
Chornenkyy, Y., Gama, A. P., Felicelli, C., Khurram, N., Booth, A. L., Leventhal, J. R., Ramsey, G. E., & Yang, G. Y. (2023). Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients. American Journal of Clinical Pathology, 159(3), 255-262. https://doi.org/10.1093/ajcp/aqac150
Vancouver
Chornenkyy Y, Gama AP, Felicelli C, Khurram N, Booth AL, Leventhal JR, et al. Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients. American Journal of Clinical Pathology. 2023;159(3):255-262. doi:10.1093/ajcp/aqac150
BibTeX
@article{Chornenkyy2023,
author = {Chornenkyy, Yevgen and Gama, Alcino Pires and Felicelli, Christopher and Khurram, Nigar and Booth, Adam L and Leventhal, Joseph R and Ramsey, Glenn Eugene and Yang, Guang-Yu},
title = {Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients},
journal = {American Journal of Clinical Pathology},
year = {2023},
volume = {159},
number = {3},
pages = {255--262},
doi = {10.1093/ajcp/aqac150}
}
EUVIMED